Catherine Mela
Executive Director, Head Biomarker Operations GlaxoSmithKline
Dr Catherine Mela is Head of Biomarker Operations, within GSK. In her role, Catherine is accountable for leading the Scientific Operations and Data Operations teams, driving the execution of precision medicine project strategies with efficiency and quality.
Catherine has gained broad experience in laboratory and bio-sample operations, while leading Human Biological Sample operational and governance teams in AstraZeneca and Roche.
Prior to working in pharma, Catherine’s background was in Clinical research within the NHS. She holds a PhD from Imperial College on ‘The impact of treatment strategies on immune responses in HIV-1 infection’. Catherine is a fellow of the institute of leadership and is passionate about professional development, mentorship and creating a supportive environment for individuals within her teams.
Seminars
- How can early integration of a global-ready sample and biomarker strategy into clinical design reduce downstream risk of sample or data variability?
- What are the key approaches to harmonizing pre-analytical workflows, and how can they be controlled across multi-site operations?
- What innovations in digital tools are facilitating end-to-end integrity and reproducibility?
- How are sponsors ensuring consistency in biospecimen handling when working across multiple CROs or laboratory partners?
- What level of collaboration between translational scientists, clinicians, and data teams is needed to ensure biomarker hypotheses remain viable throughout trial execution?
- Thinking digital – how can we plan better and reduce handoffs of data and requirements
- How to keep track of the geopolitical changes in requirements
- Managing pre-analytics should not be left to chance!
